Pharmicell Co., Ltd. (005690.KS)
KRW 8000.0
(0.63%)
KRW 8000.0
(0.63%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -10.69 Billion KRW | -530.37% |
| 2022 | 2.48 Billion KRW | 127.73% |
| 2021 | -8.96 Billion KRW | 49.85% |
| 2020 | -17.87 Billion KRW | -31.18% |
| 2019 | -13.62 Billion KRW | 12.6% |
| 2018 | -15.58 Billion KRW | -23.52% |
| 2017 | -12.62 Billion KRW | -6.5% |
| 2016 | -11.85 Billion KRW | -6.68% |
| 2015 | -11.1 Billion KRW | 15.74% |
| 2014 | -13.18 Billion KRW | -282.85% |
| 2013 | 7.2 Billion KRW | -55.37% |
| 2012 | 16.15 Billion KRW | 38.95% |
| 2011 | 11.62 Billion KRW | 103.7% |
| 2010 | 5.7 Billion KRW | 644.71% |
| 2009 | 766.38 Million KRW | -87.92% |
| 2008 | 6.34 Billion KRW | -78.85% |
| 2007 | 30 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -4.38 Billion KRW | 40.04% |
| 2024 Q1 | -7.31 Billion KRW | 31.61% |
| 2023 Q1 | -645.62 Million KRW | -125.98% |
| 2023 Q4 | -10.69 Billion KRW | 24.16% |
| 2023 FY | -10.69 Billion KRW | -530.37% |
| 2023 Q2 | -7.52 Billion KRW | -1065.24% |
| 2023 Q3 | -14.1 Billion KRW | -87.48% |
| 2022 Q2 | -2.21 Billion KRW | 78.11% |
| 2022 FY | 2.48 Billion KRW | 127.73% |
| 2022 Q4 | 2.48 Billion KRW | -56.13% |
| 2022 Q3 | 5.66 Billion KRW | 355.38% |
| 2022 Q1 | -10.13 Billion KRW | -13.05% |
| 2021 Q1 | -16.74 Billion KRW | 6.29% |
| 2021 Q4 | -8.96 Billion KRW | 60.0% |
| 2021 Q2 | -19.62 Billion KRW | -17.15% |
| 2021 Q3 | -22.4 Billion KRW | -14.19% |
| 2021 FY | -8.96 Billion KRW | 49.85% |
| 2020 FY | -17.87 Billion KRW | -31.18% |
| 2020 Q1 | -15.54 Billion KRW | -14.08% |
| 2020 Q3 | -17.77 Billion KRW | -19.57% |
| 2020 Q4 | -17.87 Billion KRW | -0.54% |
| 2020 Q2 | -14.86 Billion KRW | 4.34% |
| 2019 Q4 | -13.62 Billion KRW | -4.49% |
| 2019 FY | -13.62 Billion KRW | 12.6% |
| 2019 Q3 | -13.03 Billion KRW | 6.96% |
| 2019 Q2 | -14.01 Billion KRW | 1.56% |
| 2019 Q1 | -14.23 Billion KRW | 8.67% |
| 2018 Q4 | -15.58 Billion KRW | -3.53% |
| 2018 Q2 | -15.6 Billion KRW | -51.47% |
| 2018 FY | -15.58 Billion KRW | -23.52% |
| 2018 Q1 | -10.3 Billion KRW | 18.36% |
| 2018 Q3 | -15.05 Billion KRW | 3.52% |
| 2017 Q1 | -11.06 Billion KRW | 6.59% |
| 2017 Q4 | -12.62 Billion KRW | 7.51% |
| 2017 FY | -12.62 Billion KRW | -6.5% |
| 2017 Q3 | -13.64 Billion KRW | -34.35% |
| 2017 Q2 | -10.15 Billion KRW | 8.25% |
| 2016 Q2 | -10.76 Billion KRW | 33.66% |
| 2016 Q4 | -11.85 Billion KRW | 7.09% |
| 2016 FY | -11.85 Billion KRW | -6.68% |
| 2016 Q3 | -12.75 Billion KRW | -18.44% |
| 2016 Q1 | -16.23 Billion KRW | -46.14% |
| 2015 Q2 | -15.15 Billion KRW | 2.96% |
| 2015 FY | -11.1 Billion KRW | 15.74% |
| 2015 Q4 | -11.1 Billion KRW | -18.82% |
| 2015 Q3 | -9.34 Billion KRW | 38.32% |
| 2015 Q1 | -15.62 Billion KRW | -18.48% |
| 2014 FY | -13.18 Billion KRW | -282.85% |
| 2014 Q3 | 3.06 Billion KRW | -38.97% |
| 2014 Q2 | 5.01 Billion KRW | 101.51% |
| 2014 Q1 | 2.48 Billion KRW | -65.47% |
| 2014 Q4 | -13.18 Billion KRW | -530.62% |
| 2013 Q3 | 15.23 Billion KRW | -12.65% |
| 2013 Q4 | 7.2 Billion KRW | -52.68% |
| 2013 Q2 | 17.44 Billion KRW | -7.37% |
| 2013 Q1 | 18.82 Billion KRW | 16.56% |
| 2013 FY | 7.2 Billion KRW | -55.37% |
| 2012 FY | 16.15 Billion KRW | 38.95% |
| 2012 Q4 | 16.15 Billion KRW | 0.0% |
| 2012 Q1 | 9.41 Billion KRW | 0.0% |
| 2011 Q3 | 6.62 Billion KRW | -37.43% |
| 2011 Q2 | 10.58 Billion KRW | 34.59% |
| 2011 Q1 | 7.86 Billion KRW | 37.8% |
| 2011 FY | 11.62 Billion KRW | 103.7% |
| 2010 Q1 | 3.38 Billion KRW | 341.42% |
| 2010 Q4 | 5.7 Billion KRW | 87.16% |
| 2010 FY | 5.7 Billion KRW | 644.71% |
| 2010 Q2 | 6.68 Billion KRW | 97.61% |
| 2010 Q3 | 3.04 Billion KRW | -54.38% |
| 2009 Q3 | -3.2 Billion KRW | -174.41% |
| 2009 Q2 | 4.3 Billion KRW | 13.15% |
| 2009 Q1 | 3.8 Billion KRW | -40.01% |
| 2009 FY | 766.38 Million KRW | -87.92% |
| 2009 Q4 | 766.38 Million KRW | 123.91% |
| 2008 Q1 | 29.8 Billion KRW | -0.66% |
| 2008 Q4 | 6.34 Billion KRW | -58.24% |
| 2008 FY | 6.34 Billion KRW | -78.85% |
| 2008 Q2 | 29.11 Billion KRW | -2.32% |
| 2008 Q3 | 15.19 Billion KRW | -47.81% |
| 2007 FY | 30 Billion KRW | 0.0% |
| 2007 Q4 | 30 Billion KRW | 2.97% |
| 2007 Q3 | 29.14 Billion KRW | 2.58% |
| 2007 Q2 | 28.4 Billion KRW | 0.24% |
| 2007 Q1 | 28.33 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | -3.06 Billion KRW | -248.502% |
| Green Cross Holdings Corporation | 1105.62 Billion KRW | 100.967% |
| Green Cross Holdings Corporation | 674.31 Billion KRW | 101.586% |
| Green Cross Corporation | 674.31 Billion KRW | 101.586% |
| GeneOne Life Science, Inc. | 8.04 Billion KRW | 232.894% |
| Celltrion, Inc. | 1325.8 Billion KRW | 100.807% |
| Samsung Biologics Co.,Ltd. | 1541.39 Billion KRW | 100.694% |
| SK bioscience Co.,Ltd. | -106.45 Billion KRW | 89.952% |
| SK Biopharmaceuticals Co., Ltd. | -61.64 Billion KRW | 82.65% |
| Prestige BioPharma Limited | -129.76 Billion KRW | 91.757% |